Fusidic acid, betamethasone valerate.
Each gram contains: Fusidic acid 20 mg, Betamethasone as valerate 1 mg.
Preserved with chlorocresol.
Pharmacology: Properties: Fucicort cream combines the potent topical antibacterial action of fusidic acid with the anti-inflammatory and antipruritic effects of betamethasone. Betamethasone valerate is a topical steroid with rapid effect in inflammatory dermatoses. Even refractory conditions can often be treated successfully. When applied topically, fusidic acid is effective against Staphylococci, Streptococci, Corynebacteria, Neisseria and certain Clostridia and Bacteroides. The antibacterial activity of fusidic acid is not diminished in the presence of betamethasone.
Fucicort cream is indicated in inflammatory dermatoses where bacterial infection is present or likely to occur. Inflammatory dermatoses include atopic eczema, discoid eczema, stasis eczema, seborrhoeic dermatitis, contact dermatitis, lichen simplex chronicus, psoriasis, discoid lupus erythematosus.
Uncovered lesions: Apply 2-3 daily applications.
Covered lesions: Less frequent applications may be adequate.
Topically applied corticosteroids can be absorbed in sufficient amounts of produce systemic effects (see Adverse Reactions).
Topical corticosteroids are contra-indicated in viral, tuberculous and fungal skin infections, perioral dermatitis, acne rosacea and ulcerative condition.
Hypersensitivity to any component.
Long-term continuous therapy should be avoided, particularly in the face, on flexures, and intertrigenous areas, and in infants and children. Topical steroids should not be used extensively in pregnancy - fetal abnormalities have been seen in animals due to systemic absorption.
Hypersensitivity has rarely been encountered. As with other topical corticosteroids, prolonged and intensive treatment may cause local atrophic changes of the skin, such as striae, thinning and dilatation of the superficial blood vessels, particularly when occlusive dressing is used or when skin folds are involved. Systemic absorption, sufficient to produce hypercorticism/adrenal suppression, can occur with prolonged or extensive use, especially when used under occlusion/napkin.
Infants and children are particularly at risk.
Caution should be exercised if a topical steroid is used near the eye. Glaucoma might be the result if the preparation enters the eye.
No known drug interaction to date.
Incompatibilities: No known incompatibilities to date.
D07CC01 - betamethasone and antibiotics ; Belongs to the class of potent (group III) corticosteroids, in combination with antibiotics. Used in the treatment of dermatological diseases.